Freeport-McMoRan (FCX) Analysts See $0.24 EPS, Heron Therapeutics (HRTX) SI Decreased By 21.48%

June 20, 2017 - By Darrin Black

Analysts expect Freeport-McMoRan Inc (NYSE:FCX) to report $0.24 EPS on July, 25.They anticipate $0.26 EPS change or 1,300.00% from last quarter’s $-0.02 EPS. FCX’s profit would be $349.30M giving it 11.92 P/E if the $0.24 EPS is correct. After having $0.15 EPS previously, Freeport-McMoRan Inc’s analysts see 60.00% EPS growth. About 65 shares traded. Freeport-McMoRan Inc (NYSE:FCX) has risen 6.83% since June 20, 2016 and is uptrending. It has underperformed by 9.87% the S&P500.

Heron Therapeutics Incorporated (NASDAQ:HRTX) had a decrease of 21.48% in short interest. HRTX’s SI was 15.71M shares in June as released by FINRA. Its down 21.48% from 20.01M shares previously. With 625,700 avg volume, 25 days are for Heron Therapeutics Incorporated (NASDAQ:HRTX)’s short sellers to cover HRTX’s short positions. The stock increased 6.38% or $0.9 during the last trading session, reaching $15. About shares traded. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 20.92% since June 20, 2016 and is downtrending. It has underperformed by 37.62% the S&P500.

Among 8 analysts covering Heron Therapeutics (NASDAQ:HRTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 13 analyst reports since August 3, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, August 10 by Brean Capital. On Wednesday, September 2 the stock rating was initiated by Bank of America with “Buy”. Lake Street initiated Heron Therapeutics Inc (NASDAQ:HRTX) on Thursday, December 10 with “Buy” rating. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Jefferies on Wednesday, September 23. The company was maintained on Monday, August 3 by Brean Capital. On Wednesday, September 23 the stock rating was maintained by Leerink Swann with “Outperform”. The firm earned “Buy” rating on Wednesday, October 26 by Aegis Capital. The firm has “Buy” rating by Cowen & Co given on Friday, May 26. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Aegis Capital on Thursday, June 1.

Heron Therapeutics, Inc. is a biotechnology firm engaged in developing pharmaceutical products for patients suffering from cancer or pain. The company has market cap of $817.04 million. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. It currently has negative earnings. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Among 19 analysts covering Freeport-McMoran Copper & Gold (NYSE:FCX), 5 have Buy rating, 4 Sell and 10 Hold. Therefore 26% are positive. Freeport-McMoran Copper & Gold had 59 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Macquarie Research on Friday, January 8. The stock of Freeport-McMoRan Inc (NYSE:FCX) has “Buy” rating given on Friday, September 11 by Gabelli. On Monday, October 3 the stock rating was upgraded by Deutsche Bank to “Buy”. Barclays Capital initiated Freeport-McMoRan Inc (NYSE:FCX) rating on Wednesday, March 30. Barclays Capital has “Equal-Weight” rating and $9 target. FBR Capital maintained it with “Mkt Perform” rating and $13 target in Friday, February 3 report. CLSA downgraded the shares of FCX in report on Tuesday, April 19 to “Sell” rating. Cowen & Co maintained the shares of FCX in report on Friday, July 24 with “Outperform” rating. The firm has “Hold” rating given on Thursday, November 17 by Deutsche Bank. The rating was downgraded by Jefferies on Tuesday, January 12 to “Hold”. Deutsche Bank maintained the shares of FCX in report on Monday, May 2 with “Hold” rating.

Investors sentiment decreased to 0.96 in 2016 Q4. Its down 0.02, from 0.98 in 2016Q3. It is negative, as 61 investors sold Freeport-McMoRan Inc shares while 223 reduced holdings. 99 funds opened positions while 175 raised stakes. 995.10 million shares or 5.90% more from 939.67 million shares in 2016Q3 were reported. Oxbow Advsr Limited Liability Corp accumulated 0.02% or 14,664 shares. Horizon Kinetics Ltd Liability Corporation has invested 0.06% of its portfolio in Freeport-McMoRan Inc (NYSE:FCX). Fayez Sarofim & Com holds 0.02% of its portfolio in Freeport-McMoRan Inc (NYSE:FCX) for 234,767 shares. Goldman Sachs Gru Incorporated owns 12.50 million shares. Advisory Serv Inc reported 0.07% in Freeport-McMoRan Inc (NYSE:FCX). Cambridge Invest Advisors reported 85,366 shares. Sumitomo Mitsui Trust has invested 0.07% in Freeport-McMoRan Inc (NYSE:FCX). Tiaa Cref Mngmt Lc invested in 0.07% or 6.88M shares. Highvista Strategies Ltd Liability Co invested 0.23% in Freeport-McMoRan Inc (NYSE:FCX). Mackenzie reported 0% in Freeport-McMoRan Inc (NYSE:FCX). Independent Portfolio Consultants holds 136 shares. Schwab Charles Investment Mngmt holds 5.16M shares or 0.07% of its portfolio. Amica Pension Fund Board Of Trustees holds 0.13% or 79,164 shares in its portfolio. Sei Investments invested 0.03% in Freeport-McMoRan Inc (NYSE:FCX). Massachusetts-based Boston has invested 0.01% in Freeport-McMoRan Inc (NYSE:FCX).

Freeport-McMoRan Inc. is a mining company. The company has market cap of $16.65 billion. The Firm operates through geographical assets with proven and probable reserves of copper, gold and molybdenum, and traded copper producer. It has a 37.21 P/E ratio. The Company’s divisions include refined copper products, copper in concentrate, gold, molybdenum, oil and other.

Since February 1, 2017, it had 0 insider buys, and 4 selling transactions for $2.34 million activity. The insider MADONNA JON C/ sold 14,000 shares worth $232,498. WHITMIRE C DONALD JR sold 57,620 shares worth $888,500. Another trade for 77,500 shares valued at $1.18 million was made by Conger Harry M. IV on Wednesday, February 15.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: